The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo‐controlled studies

ConclusionDesvenlafaxine 50 mg/day significantly improved depressive symptoms compared with placebo in major depressive disorder patients with clinically relevant anxiety symptoms. Improvement in the HAM‐D17 total score was similar for anxious/nonanxious groups. Copyright © 2014 John Wiley & Sons, Ltd.

Source: Human Psychopharmacology: Clinical and Experimental - August 11, 2014 Category: Psychiatry Authors: Susan G. Kornstein, Christine J. Guico‐Pabia, Rana S. Fayyad Tags: Research Article Source Type: research